摘要
目的 :评价低分子量肝素与香丹注射液联用治疗急性缺血性脑梗死的临床疗效和安全性。方法 :10 0例病人分为 3组 ,联用组 4 0例 ,用低分子量肝素 5 0 0 0抗Xa国际单位腹部脐周皮下注射 ,每12h 1次 ,香丹注射液 4 0ml加入 5 %葡萄糖注射液5 0 0ml中 ,静脉滴注 ,每天 1次 ;低分子量肝素组 30例 ,只用低分子量肝素治疗 ;香丹组 30例 ,只用香丹注射液治疗。 3组治疗时间均为 10～ 14d。结果 :联用组的临床疗效高于低分子量肝素组和香丹组(P <0 .0 5 )。不良反应发生率 3组间无显著的统计学意义 (P >0 .0 5 )。结论 :低分子量肝素和香丹注射液联用治疗急性缺血性脑梗死效果优于单用其中一种药物治疗 ,不良反应发生率低 ,安全有效。
AIM: To evaluate the clinical therapeutic effects and safety of low molecular weight heparin combined with xiangdan injection in patients with acute cerebral infarction. METHODS: 100 cases of patients with acute cerebral infarction were divided into three groups. The combination group (40 cases) was treated with low molecular weight heparin calcium of 5000 IU, sc, q 12 h, and xiangdan injection 40ml added into glucose injection 500 ml, iv gtt, qd, and the low molecular weight heparin group(30 cases)was treated with low molecular weight heparin calcium for injection only. The xiangdan group (30 cases) was treated with xiangdan injection only. The treating time was 10d in three groups. RESULTS: The cure rate in the combination group was the highest among the three groups (P< 0.05 ), and the rate of adverse reaction did not show significance (P> 0.05 )among three groups. CONCLUSION: The low molecular weight heparin combined with xiangdan injection is effective and safe in the treatment of patients with acute cerebral infarction.
出处
《中国临床药理学与治疗学》
CAS
CSCD
2003年第4期465-467,共3页
Chinese Journal of Clinical Pharmacology and Therapeutics
关键词
药效学
低分子量肝素
香丹
脑梗死
效果
评价
pharmacodynamics
low molecular weight heparin
xiangdan
acute cerebral infarction
drug evaluation
